Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma
Authors
Keywords
-
Journal
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
Volume 14, Issue 7, Pages 662-681
Publisher
Wiley
Online
2016-07-04
DOI
10.1111/ddg.13047
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association of adverse events and tumor response in melanoma patients treated with tremelimumab.
- (2017) D. Pavlov et al. JOURNAL OF CLINICAL ONCOLOGY
- New-Onset Mediastinal and Central Nervous System Sarcoidosis in a Patient with Metastatic Melanoma Undergoing CTLA4 Monoclonal Antibody Treatment
- (2016) Kevin P. Murphy et al. Oncology Research and Treatment
- Systematic review: colitis associated with anti-CTLA-4 therapy
- (2015) A. Gupta et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Ipilimumab-associated Hepatitis
- (2015) Melanie Johncilla et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Ipilimumab Granulomatous Interstitial Nephritis
- (2015) Bijin Thajudeen et al. AMERICAN JOURNAL OF THERAPEUTICS
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
- (2015) Anne Bertrand et al. BMC Medicine
- Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report
- (2015) Juan Martin-Liberal et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis
- (2015) Omar Abdel-Rahman et al. Future Oncology
- Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma
- (2015) Douglas B. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
- (2015) Hansje-Eva Teulings et al. JOURNAL OF CLINICAL ONCOLOGY
- Toxicities of Immunotherapy for the Practitioner
- (2015) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Autoimmune Colitis and Subsequent CMV-induced Hepatitis After Treatment With Ipilimumab
- (2015) Ugur Uslu et al. JOURNAL OF IMMUNOTHERAPY
- Vogt-Koyanagi-Harada-like Syndrome After CTLA-4 Inhibition With Ipilimumab for Metastatic Melanoma
- (2015) Jason N. Crosson et al. JOURNAL OF IMMUNOTHERAPY
- Peripheral Neuropathy Associated With Ipilimumab
- (2015) Iyavut Thaipisuttikul et al. JOURNAL OF IMMUNOTHERAPY
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy
- (2015) Mizuki Nishino et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab-induced Ocular and Orbital Inflammation—A Case Series and Review of the Literature
- (2015) Evangelia Papavasileiou et al. OCULAR IMMUNOLOGY AND INFLAMMATION
- Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
- (2015) Alexander Faje Pituitary
- Immune-mediated adverse events of anticytotoxic T lymphocyte–associated antigen 4 antibody therapy in metastatic melanoma
- (2015) Shannon K. Quirk et al. Translational Research
- Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
- (2015) Martina Sanlorenzo et al. JAMA Dermatology
- Bilateral Choroidopathy and Serous Retinal Detachments During Ipilimumab Treatment for Cutaneous Melanoma
- (2015) Dimosthenis Mantopoulos et al. JAMA Ophthalmology
- Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
- (2015) Ahmad A. Tarhini et al. Journal for ImmunoTherapy of Cancer
- Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
- (2015) Heinz Läubli et al. Journal for ImmunoTherapy of Cancer
- Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome
- (2015) Benjamin P Geisler et al. Journal for ImmunoTherapy of Cancer
- Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study
- (2014) L. Min et al. CLINICAL CANCER RESEARCH
- Long-Lasting Responses under Treatment with Ipilimumab: An Argument against Maintenance Therapy?
- (2014) Julika Dick et al. DERMATOLOGY
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- (2014) Mabel Ryder et al. ENDOCRINE-RELATED CANCER
- Kidney injuries related to ipilimumab
- (2014) Hassane Izzedine et al. INVESTIGATIONAL NEW DRUGS
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Lambrolizumab induced central nervous system (CNS) toxicity
- (2014) Jacob J. Mandel et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma
- (2014) B. Liao et al. NEURO-ONCOLOGY
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- Ipilimumab in the treatment of metastatic melanoma: management of adverse events
- (2014) Giuseppina Della Vittoria Scarpati et al. OncoTargets and Therapy
- Late-Onset Paraplegia after Complete Response to Two Cycles of Ipilimumab for Metastatic Melanoma
- (2014) Grainne M. O'Kane et al. Oncology Research and Treatment
- Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma
- (2013) Bobeck S. Modjtahedi et al. Cutaneous and Ocular Toxicology
- Hypophysitis Caused by Ipilimumab in Cancer Patients: Hormone Replacement or Immunosuppressive Therapy
- (2013) A. Lammert et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Ipilimumab associated hepatitis: imaging and clinicopathologic findings
- (2013) Kyung Won Kim et al. INVESTIGATIONAL NEW DRUGS
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
- (2013) Caroline J. Voskens et al. PLoS One
- Drug-Associated Polymyalgia Rheumatica/Giant Cell Arteritis Occurring in Two Patients After Treatment With Ipilimumab, an Antagonist of CTLA-4
- (2013) Barbara L. Goldstein et al. Arthritis & Rheumatology
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- 18F-FDG PET/CT imaging of an anti-CTLA-4 antibody-associated autoimmune pancolitis
- (2011) Lode Goethals et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Hemophilia A Induced by Ipilimumab
- (2011) Julie Delyon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Drug-Induced Graves Disease From CTLA-4 Receptor Suppression
- (2011) Gary Borodic et al. OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- (2010) S. J. O'Day et al. ANNALS OF ONCOLOGY
- Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
- (2010) Le Min et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma
- (2010) Katharina C. Kähler et al. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications
- (2010) Anna Maria Di Giacomo et al. SEMINARS IN ONCOLOGY
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started